Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials (Q4335635)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials |
scientific article; zbMATH DE number 1005954
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials |
scientific article; zbMATH DE number 1005954 |
Statements
Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials (English)
0 references
12 June 1997
0 references
two-stage clinical trials
0 references
phase II trials
0 references
early stopping
0 references
Simon designs
0 references
multiple endpoints
0 references
group sequential designs
0 references
clinical response
0 references
toxicity
0 references
maximum expected accrual
0 references
control of error rates
0 references
0.90523875
0 references
0.86872464
0 references
0.8482796
0 references
0.8481449
0 references
